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Obesity has increased over the last 20 years, from a condition affecting 
only a small portion of populations in developed countries, into a global 
pandemic.1  The impact of obesity can be appreciated in the context of the 
populations at risk, and it is estimated that >1 billion adults worldwide are 
overweight (BMI >25 kg/m2), 300 million of whom are clinically obese (BMI >30 
kg/m2).2  In the United States, 65% of adults are overweight, and 32.2% of them 
are obese, a prevalence that has doubled over 20 years.3  In industrialized 
countries, obesity rates have tripled, coinciding with adoption of a Western 
lifestyle.4  Further, the growing worldwide rates of childhood obesity have 
reached epidemic values in developed countries.5  This global obesity 
pandemic reflects genetic susceptibility, availability of high-energy foods, and 
decreased physical activity.  Accelerating rates of obesity have profound 
health and economic consequences.  Obesity is associated with a myriad of 
co-morbidities, including type II diabetes, coronary artery disease, obstructive 
sleep apnea, stroke, cancer, hypertension, osteoarthritis, and liver and biliary 
disease which collectively increase mortality.6  Indeed, the health care impact 
of chronic obesity exceeds that of smoking or alcohol abuse.7  National health 
care costs of obesity are $70-100 billion, and if this trend continues, in 15 years 
20% of health care costs in the United States will be attributed to the chronic 
diseases associated with obesity.8  
Collectively, these considerations underscore the health and economic 
imperative to develop novel therapeutic approaches to combat obesity and its 
co-morbidities.  In that context, overweight and obese individuals who receive 
assistance from their health care providers to lose weight are three times more 
likely to attempt weight loss.9  The most common approach to medical weight 
management is counseling and lifestyle modification.  However, while patients 
enrolled in these programs initially lose weight, they usually regain 30-35% of their 
lost weight within one year following treatment, and >50% of patients return to 
their baseline weight by five years.10, 11  At present, only two drugs, orlistat and 
sibutramine, are approved for the long-term treatment of obesity.  However, 
due to their inherent cardiovascular and gastrointestinal adverse effects, 
respectively, these drugs are often only utilized as rescue therapy for patients 
who fail diet and exercise.  The scope of the obesity problem and the absence 
of available long-term solutions highlights the unmet clinical need for safe and 
effective pharmacotherapeutics to induce and maintain weight loss. 
Endogenous Hormones 
The adipose tissue-derived hormone, leptin, was one of the earliest 
endogenous hormones to be developed as an anti-obesity therapeutic.  
However, early leptin trials failed reflecting the evolution of leptin resistance in 
obese individuals.  Recent insights into the molecular mechanisms underlying 
leptin signaling has revealed novel pharmacological approaches to increase 
receptor sensitivity, and leptin has re-emerged as a promising anti-obesity drug 
candidate.  Indeed, chemical chaperones (4-phenyl butyric acid (PBA), 
tauroursodeoxycholic acid (TUDCA)), which resolve stress in the endoplasmic 
reticulum, increase leptin sensitivity in mice12.  Pramlintide, a synthetic analog of 
pancreatic amylin, also sensitizes mice to the effects of leptin, and 
pramlintide/metreleptin combination therapy is currently entering phase III trials 
after producing positive results in phase II testing.13 
Glucagon-like peptide-1 (GLP-1) is an incretin secreted by the ileum and 
proximal colon which suppresses appetite in rodents and humans.  In clinical 
trials, two proteolysis-resistant GLP-1 analogs (exenatide, liraglutide) induced 
weight loss.  Further, a long-acting release formulation of exenatide (exenatide-
LAR), injected once weekly, as well as nasal and transdermal formulations of 
exenatide, also are in early clinical development.14  Moreover, testing of a long-
acting GLP-1 analogue (NN9924), which utilizes sodium N-[8-(2-hydroxybenzoyl) 
amino] caprylate (SNAC) carrier technology to allow oral dosing, was initiated.15 
Oxyntomodulin (OXM) is secreted post-prandially along with GLP-1 and 
has central anorectic effects.  Repeated injections of OXM significantly reduced 
caloric intake and increased energy expenditure in overweight and obese 
subjects.16, 17  A long-acting OXM analogue, TKS1225, has been developed.18 
PYY is a satiety hormone secreted post-prandially by cells of the ileum and 
proximal colon which effectively reduces appetite in a dose-dependent 
manner.19  Intranasal delivery of PYY (3-36) has been developed as an 
alternative delivery method to subcutaneous injection, and over 12 weeks of 
intranasal therapy PYY (200 µg, 600 µg) induced placebo-adjusted mean weight 
losses of 1.4 kg and 2.3 kg, respectively.  However, nausea and vomiting caused 
>50% of subjects receiving 600 µg PYY (3-36) to withdraw from the study.20  
Ghrelin, secreted by the stomach, is the only known circulating orexigenic 
hormone.  A vaccine comprising ghrelin conjugated to the hapten keyhole 
limpet hemocyanin decreased feeding and induced weight loss in rodent 
models.21  An RNA spiegelmer, NOX-B11, which blocked the orexigenic activity 
of exogenous ghrelin22, as well as small molecule ghrelin antagonists, are 
currently in early clinical and preclinical testing, respectively.23  
Neuropeptide Signaling Modulators 
Appetite and energy balance are primarily controlled by neuropeptide 
signaling within the hypothalamus.  The arcuate nucleus is the principle signaling 
site for peripheral appetite-regulating hormones and contains neurons 
expressing the orexigenic neuropeptides, neuropeptide Y (NPY)/agouti-related 
peptide (AgRP) or the anorexigenic neuropeptide pro-opiomelanocortin 
(POMC). 
The orexigenic activity of NPY is linked to signaling at Y1- and Y5-receptors, 
and an orally active Y5-receptor antagonist (MK-0557) has been developed.  
However, this drug did not induce clinically meaningful weight loss in a 1-year 
clinical trial.24  Another Y5-receptor antagonist (S-2367) was modestly effective in 
clinical testing.25  Since signaling at the Y1- receptor predominates in the 
appetite-stimulating effects of NPY, Y1-receptor antagonism or a combination 
Y1/Y5-receptor antagonism may prove more effective in reducing appetite and 
inducing weight loss.  
Due to their pre-synaptic inhibition of NPY release, Y2- and Y4-receptors, 
which are the targets of the satiety hormones PYY and pancreatic polypeptide, 
respectively, have been explored as molecular anti-obesity targets.26  Currently, 
two drugs: obinepitide, a Y2/Y4- receptor agonist, and TM30339, a selective Y4 
receptor agonist, are in phase I/II clinical trials.27  Additionally, a specific AgRP 
inhibitor (TTT-435)28, and BMS-830216, a pharmacological antagonist of signaling 
of the orexigenic neuropeptide, melanin-concentrating hormone, are in early 
clinical testing.29  
Modulators of Monoamine Neurotransmission 
Several monoamine neurotransmitters, including norepinephrine, 
dopamine, serotonin, and histamine, regulate appetite and energy balance.  
Bupropion, a norepinephrine and dopamine reuptake inhibitor currently 
marketed as an anti-depressant, induced long-lasting weight loss in normal and 
depressed obese patients.30, 31  Thus, bupropion could be a useful therapeutic 
tool in the management of obese patients suffering from depression.  
Serotonergic drugs suppress appetite by stimulating central 5-HT2C receptors.32  
Lorcaserin hydrochloride (ADP-356), a selective 5HT2C agonist, effectively 
induced weight loss in phase II/III testing, and a New Drug Application (NDA) 
was recently filed for this agent .33  Central histamine signaling also regulates 
appetite, and inhibition of H1-histamine receptor signaling by antipsychotic 
medications may underlie the weight gain commonly experienced with their 
use.  H3-histamine receptors regulate histamine signaling by inhibiting 
presynaptic histamine neurotransmission.  Therefore, both H1-receptor agonists 
and H3-receptor antagonists are being developed as anti-obesity therapeutics. 
Peripheral Modulators of Metabolism and Lipogenesis 
Insulin resistance, commonly experienced by obese patients, may be an 
adaptive mechanism to prevent further fat accumulation, as insulin resistance is 
associated with a decreased risk of further weight gain.  Thus, decreasing insulin 
signaling may be an effective means of inducing weight loss.  Diazoxide, a 
potassium channel opener that inhibits insulin secretion, induced weight loss in 
clinical testing and may have utility as an anti-obesity therapeutic.34  However, 
decreasing insulin secretion produces a serious risk of hyperglycemia, and the 
long-term safety of this agent must be defined. 
The β3-adrenergic receptor (β3AR) is expressed by adipocytes, and its 
activation induces lipolysis and increases fat oxidation.35  However, trials 
studying β3 agonists as potential anti-obesity drugs failed, likely reflecting the low 
expression levels of β3ARs in human adipocytes or the limited ability of these 
agents to activate β3ARs in adipose tissue.  Trials investigating β3AR agonists for 
inducing weight loss are ongoing. 
High circulating glucocorticoid levels produce the features of the 
metabolic syndrome, including central obesity and insulin resistance.  In that 
context, 11β-Hydroxysteroid dehydrogenase type 1 (HSD1) converts inactive 
cortisone to active cortisol in peripheral tissues.  Selective 11β-HSD1 inhibitors are 
being developed to improve insulin sensitivity and induce weight loss. 
Activated adipocytes produce a wide array of vascular growth factors 
and matrix metalloproteases to facilitate angiogenesis important for the growth 
of adipose tissue.  Indeed, angiogenesis inhibition decreased weight gain in 
rodents36 and may be useful in preventing the growth of adipose tissue in 
humans. 
Finally, modulation of the transcription of genes involved in lipogenesis 
and cellular metabolism may be a productive strategy for inducing weight loss.  
Sirtuin-1 (SIRT1), an NAD-dependent deacetylase, binds to peroxisome 
proliferator-activated receptor-γ (PPAR-γ) in adipose tissue, repressing the 
transcription of genes involved in fat storage.37  SIRT1 also enhances oxidative 
metabolism in brown adipose tissue, liver, and skeletal muscle by interacting 
with PGC-1α and inducing the expression of genes involved in mitochondrial 
oxidative metabolism.38  SIRT1-activating drugs, which induce weight loss in 
rodents, are in early clinical trials to explore their utility in the treatment of obesity 
and metabolic diseases. 
Combination Therapeutics 
Combination therapy, which has been an effective strategy in the 
treatment of a variety of diseases, including hypertension, cancer, heart 
disease, and infectious diseases, may hold promise for the treatment of obesity.  
Three combination drugs, Contrave (bupropion + naltrexone), Empatic 
(bupropion + zonisamide), and Qnexa (phentermine + topiramate), have shown 
great promise in clinical testing.39  While most of these agents have proven 
individual efficacy, combination therapy amplifies clinical effects at lower 
individual drug doses, reducing the risk of adverse effects. 
Conclusions 
Molecular mechanisms controlling appetite, nutrient exposure, and 
energy balance are only beginning to emerge, and elucidation of these 
pathways will produce novel therapeutic targets for obesity.40  Further, new 
technologies permitting more practical delivery methods, including oral, 
intranasal, and transdermal formulations, will allow drugs currently limited by 
their route of administration to achieve greater acceptance and patient 
compliance.  The global health and economic consequences of obesity in the 
context of the ineffectiveness of lifestyle changes on producing durable weight 
loss highlight the critical unmet medical need for additional therapeutic 
approaches that achieve widespread integration into the clinical management 
of overweight and obese patients. 
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